Novo Nordisk has developed a new version of the insulin analogue, called Fiasp, which added another DKK 1.6 billion to the fast-acting insulin pot last year and has patent protection to 2030.

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term ...

Mounjaro has been approved for both type 2 diabetes and weight loss; however, access will be limited by strict eligibility ...

Introduction Globally, one in two people needing insulin lack access. High prices and poor availability are thought to be key contributors to poor insulin access. However, few studies have assessed ...

Beyond dizziness, you want to look out for the sudden onset of “the worst headache of your life and any loss of limb function ...

Inhaled insulin is an “important alternative” to injected rapid-acting analog insulin for children and teens with diabetes, ...

Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the ...